Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
1.09T
Market cap1.09T
Price-Earnings ratio
38.84
Price-Earnings ratio38.84
Dividend yield
0.59%
Dividend yield0.59%
Average volume
2.22M
Average volume2.22M
High today
$1,177.07
High today$1,177.07
Low today
$1,139.98
Low today$1,139.98
Open price
$1,149.25
Open price$1,149.25
Volume
1.48M
Volume1.48M
52 Week high
$1,292.65
52 Week high$1,292.65
52 Week low
$783.85
52 Week low$783.85

Stock Snapshot

With a market cap of 1.09T, Eli Lilly(LLY) trades at $1,160.05. The stock has a price-to-earnings ratio of 38.84 and currently yields dividends of 0.59%.

During the trading session on 2026-10-06, Eli Lilly(LLY) shares reached a daily high of $1,177.07 and a low of $1,139.98. At a current price of $1,160.05, the stock is +1.8% higher than the low and still -1.4% under the high.

Trading activity shows a volume of 1.48M, compared to an average daily volume of 2.22M.

The stock's 52-week range extends from a low of $783.85 to a high of $1,292.65.

The stock's 52-week range extends from a low of $783.85 to a high of $1,292.65.

LLY News

24/7 Wall St. 3h
Prediction: LLY Has Another Massive Growth Opportunity Beyond Weight Loss

Eli Lilly built its reputation on weight loss drugs, but a fast-growing portfolio in oncology, immunology, and neuroscience just posted triple-digit gains, and...

Prediction: LLY Has Another Massive Growth Opportunity Beyond Weight Loss
TipRanks 3h
Eltrekibart Phase 1 Completion: What Eli Lilly’s Latest Trial Means for LLY Investors

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. This Phase 1 study, officially titled “A Phase 1, Open-Label, Single Dose Stud...

TipRanks 3h
Lilly’s New Basal Insulin Candidate Clears Key Early Trial Milestone

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Eli Lilly and Company (LLY) has completed a Phase 1 trial titled “A Four-Part,...

Analyst ratings

84%

of 32 ratings
Buy
84.4%
Hold
9.4%
Sell
6.3%

More LLY News

The Motley Fool 7h
Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026?

The race for dominance in weight-loss and diabetes treatments has reached a fever pitch. Investors choosing between Eli Lilly and (LLY +0.02%) and Novo Nordisk...

Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026?
Simply Wall St 10h
Eli Lilly Just Drew Fresh Attention, So What Is The Market Weighing?

Eli Lilly (LLY) just expanded its collaboration with Gate Bioscience to pursue additional molecular gate therapeutics, a research heavy area that often attracts...

Eli Lilly Just Drew Fresh Attention, So What Is The Market Weighing?
The Motley Fool 24h
Eli Lilly Has Been a Growth Beast, but This Is the Riskiest Part About Its Stock

Eli Lilly (LLY +0.02%) is the only healthcare stock in the trillion-dollar club, and for good reason. Its business has been booming due to its successful GLP-1...

Eli Lilly Has Been a Growth Beast, but This Is the Riskiest Part About Its Stock
TipRanks 1d
Eli Lilly Stock Gains on Regulatory Win for Experimental Cancer Drug

The stock of Eli Lilly (LLY) is up about 1% on Oct. 5 after the company secured a regulatory win for one of its experimental cancer drugs called Olomorasib. The...

TipRanks 1d
Eli Lilly treatment of pancreatic cancer granted orphan designation

Eli Lilly (LLY) was granted FDA orphan designation for olomorasib for the treatment of pancreatic cancer, according to a post to the agency’s website. Publishe...

Benzinga 1d
FDA Expands Approval for Eli Lilly Therapy in Untreated Leukemia Patients

The U.S. Food and Drug Administration on Friday approved an additional indication of Jaypirca (pirtobrutinib), enabling Eli Lilly and Co. (NYSE:LLY) to market t...

FDA Expands Approval for Eli Lilly Therapy in Untreated Leukemia Patients
The Motley Fool 2d
Forget Zepbound: Eli Lilly's Next Weight-Loss Drug Could Be Its Biggest Blockbuster Yet

Healthcare stocks have lagged broader equities over the past few years, but the company that is now the largest in that sector, Eli Lilly (LLY -0.61%), has deli...

Forget Zepbound: Eli Lilly's Next Weight-Loss Drug Could Be Its Biggest Blockbuster Yet

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.